Clinical trial
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With…
NCT00234429 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00234429 |
|---|---|
| Title | A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma |
| Official title | A Randomized, Placebo-Controlled, Double-Blind Phase 2b Study of Raltitrexed (Tomudex) and ZD1839 (Iressa) Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, raltitrexed |
| Enrollment | 74 |
| Start date | Nov 1, 2003 |
| Completion | Jun 1, 2006 |
| First posted | Oct 7, 2005 |
| Last update posted | Dec 18, 2007 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: